Xeris Biopharma Holdings, Inc. (LON:0A8E)

Xeris Biopharma Holdings Statistics

Total Valuation

LON:0A8E has a market cap or net worth of GBP 840.32 million. The enterprise value is 962.03 million.

Market Cap	840.32M
Enterprise Value	962.03M

Important Dates

The next estimated earnings date is Monday, March 2, 2026.

Earnings Date	Mar 2, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	165.92M
Shares Outstanding	n/a
Shares Change (YoY)	+8.48%
Shares Change (QoQ)	+11.39%
Owned by Insiders (%)	5.18%
Owned by Institutions (%)	59.18%
Float	157.32M

Valuation Ratios

PE Ratio	n/a
Forward PE	31.75
PS Ratio	4.24
PB Ratio	-1,311.91
P/TBV Ratio	n/a
P/FCF Ratio	113.24
P/OCF Ratio	106.99
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 35.15, with an EV/FCF ratio of 129.64.

EV / Earnings	-82.68
EV / Sales	4.93
EV / EBITDA	35.15
EV / EBIT	82.54
EV / FCF	129.64

Financial Position

The company has a current ratio of 1.93

Current Ratio	1.93
Quick Ratio	1.25
Debt / Equity	n/a
Debt / EBITDA	6.90
Debt / FCF	25.83
Interest Coverage	0.54

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	2.88%
Return on Invested Capital (ROIC)	3.98%
Return on Capital Employed (ROCE)	6.26%
Weighted Average Cost of Capital (WACC)	9.36%
Revenue Per Employee	502,513
Profits Per Employee	-29,531
Employee Count	394
Asset Turnover	0.77
Inventory Turnover	0.73

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +97.24% in the last 52 weeks. The beta is 0.94, so LON:0A8E's price volatility has been similar to the market average.

Beta (5Y)	0.94
52-Week Price Change	+97.24%
50-Day Moving Average	7.25
200-Day Moving Average	6.69
Relative Strength Index (RSI)	40.11
Average Volume (20 Days)	1,851

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.30

Income Statement

In the last 12 months, LON:0A8E had revenue of GBP 197.99 million and -11.64 million in losses. Loss per share was -0.08.

Revenue	197.99M
Gross Profit	167.41M
Operating Income	11.83M
Pretax Income	-11.64M
Net Income	-11.64M
EBITDA	20.86M
EBIT	11.83M
Loss Per Share	-0.08

Balance Sheet

The company has 68.14 million in cash and 191.68 million in debt, with a net cash position of -123.54 million.

Cash & Cash Equivalents	68.14M
Total Debt	191.68M
Net Cash	-123.54M
Net Cash Per Share	n/a
Equity (Book Value)	-640,532
Book Value Per Share	-0.00
Working Capital	80.21M

Cash Flow

In the last 12 months, operating cash flow was 7.85 million and capital expenditures -433,717, giving a free cash flow of 7.42 million.

Operating Cash Flow	7.85M
Capital Expenditures	-433,717
Free Cash Flow	7.42M
FCF Per Share	n/a

Margins

Gross margin is 84.56%, with operating and profit margins of 5.98% and -5.88%.

Gross Margin	84.56%
Operating Margin	5.98%
Pretax Margin	-5.88%
Profit Margin	-5.88%
EBITDA Margin	10.53%
EBIT Margin	5.98%
FCF Margin	3.75%

Dividends & Yields

LON:0A8E does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.48%
Shareholder Yield	-8.48%
Earnings Yield	-1.38%
FCF Yield	0.88%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0A8E has an Altman Z-Score of -0.2 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.2
Piotroski F-Score	6